aDepartment of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Division of Medical Oncology, Rionero
bUnit of Medical Oncology, Department of Oncology, Ospedale San Donato, Arezzo
cDepartment of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Siena, Italy
dDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Moorabbin Campus, Bentleigh East, Victoria, Australia
Received 12 February 2019 Revised form accepted 19 March 2019
Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, www.anti-cancerdrugs.com.
This work has been reported as an abstract in Abstract Book: Tumori J 2018; 104 (Suppl): 6–224.
Correspondence to Giandomenico Roviello, MD, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, Division of Medical Oncology, via Padre Pio 1, 85028 Rionero, Italy Tel: + 39 097 272 6255; fax: + 39 097 272 6716; e-mail: [email protected]
